CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical ...
BAAR, Switzerland, July 07, 2025--(BUSINESS WIRE)--CorFlow Therapeutics AG (CorFlow), a pioneering company in the field of cardiac care targeting microvascular disease, today announced that the U.S.
BAAR, Switzerland--(BUSINESS WIRE)--CorFlow Therapeutics AG (www.corflow-therapeutics.ch) today announced that the company has completed the 2nd close of its Seed+ financing round. To date, and since ...
CorFlow Therapeutics AG, a clinical-stage company, has announced the interim positive results of its MOCA I (Microvascular Obstruction with CoFI System Assessment) study at EuroPCR in Paris, France.
CorFlow Therapeutics AG ("CorFlow") announces today that Dr. Felice Gragnano, MD, Inselspital, Bern University Hospital, Bern, Switzerland, will present a case study and the initial diagnostic results ...
Baar-headquartered CorFlow Therapeutics AG, a pioneering company in the field of cardiac care targeting microvascular disease, announced that the US Food & Drug Administration (FDA) has approved the ...
WASHINGTON, Dec. 3, 2019 /PRNewswire/ -- MCRA, LLC, a leading medical device advisory firm and Clinical Research Organization (CRO) that integrates regulatory, clinical research, reimbursement, ...
BAAR, Switzerland — CorFlow Therapeutics AG (CorFlow) is pleased to announce the appointment of Chris O’Connell as Chairman of the Board of Directors, replacing Rick Geoffrion who remains as a ...
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results